Keyphrases
Adverse Events
14%
Clinical Course
14%
Complete Response
28%
Complete Response Rate
14%
Dermatological Diseases
14%
Effective Treatment
14%
Etretinate
28%
Genital Warts
100%
High-risk Human Papillomavirus (HR-HPV)
14%
Irritant Contact Dermatitis
14%
Isotretinoin
28%
Meta-analysis
100%
Mucocutaneous Disorders
14%
Oral Isotretinoin
14%
Prospective Cohort Study
14%
Randomized Controlled Trial
14%
Recurrence Rate
14%
Regress
14%
Relapse Rate
14%
Retinoids
42%
Safe Treatment
14%
Sexually Transmitted Infections
14%
Systematic Meta-analysis
100%
Systemic Agents
14%
Systemic Retinoids
100%
Therapeutic Modalities
14%
Topical Agents
14%
Topical Retinoids
100%
Warts
14%
Medicine and Dentistry
Adverse Event
14%
Dermatological Agent
14%
Disease
14%
Disease Course
14%
Diseases
14%
Etretinate
28%
Genital Wart
100%
Irritant Dermatitis
14%
Isotretinoin
42%
Meta-Analysis
100%
Prospective Cohort Study
14%
Randomized Controlled Trial
14%
Recurrence Risk
28%
Recurrent Disease
14%
Retinoid
100%
Sexually Transmitted Disease
14%
Side Effect
14%
Systematic Review
100%
Therapeutic Modality
14%
Topical Agent
14%
Verruca Vulgaris
14%
Wart Virus
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
14%
Condyloma acuminatum
100%
Dermatological Agent
14%
Disease Course
14%
Diseases
14%
Etretinate
28%
Human Papillomavirus
14%
Irritant Dermatitis
14%
Isotretinoin
42%
Prospective Cohort Study
14%
Randomized Controlled Trial
14%
Recurrence Risk
28%
Recurrent Disease
14%
Retinoid
100%
Sexually Transmitted Disease
14%
Side Effect
14%
Topical Agent
14%
Verruca Vulgaris
14%